Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 11;75(12):2088–2096. doi: 10.1093/cid/ciac345

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022. Published by Oxford University Press on behalf of the Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Figure 2. — Level of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) anti-spike receptor-binding domain antibody in participants (A) aged <60 years, (B) participants aged ≥60 years, and (C) overall. Participants in the older age group (≥60 years old) who received a heterologous coronavirus disease 2019 vaccine booster (BBM) had significantly higher anti–SARS-CoV-2 immunoglobulin G antibodies than those who received a homologous messenger RNA booster (BBB) at days 7 and 28 post-vaccination. Data analyzed using the Student t test to compare the log₁₀ anti-spike titer. Box represents 25th and 75th percentile, line is median, with whiskers denoting extremes. *P < .05, **P < .01. Abbreviations: BBB, BNT162b2- BNT162b2- BNT162b2; BBM, BNT162b2-BNT162b2-mRNA-1273; CI, confidence interval.